SGAM
INSY

Smith Group Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Smith Group Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,271
Closed -$68K – 438
2013
Q4 		$68K Sell
5,271
-2,670
-34% -$37K ﹤0.01% 226
2013
Q3 		$93K Buy
+7,941
New +$65.2K ﹤0.01% 232

Other funds holding INSY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Smith Group Asset Management's INSY Position: Q1 2014 in Review

Smith Group Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2014, closing a stake of 5,271 shares — an estimated $68K sold.

Smith Group Asset Management first reported a position in INSY in Q3 2013 and held it in 2 quarters. The position peaked at $93K in Q3 2013. 99 funds tracked by Wall St. Rank hold INSY as of Q1 2014.

  • Smith Group Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Smith Group Asset Management sold 5,271 Insys Therapeutics, Inc. shares in Q1 2014, an estimated $68K.
  • Smith Group Asset Management first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • Smith Group Asset Management's Insys Therapeutics, Inc. position peaked at $93K in Q3 2013.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2014.

Based on Smith Group Asset Management's 13F filing for Q1 2014, filed 23 Apr 2014.